65,437 trials
COVID-19 · Lung Injury, Acute · Kidney Injury
Primary: Change in COVID Disease Status — 5.09; 5.48; 3.05; 3.00 score on a scale
Lymphoma, Non-Hodgkin · Lymphoma, Large B-Cell, Diffuse · Lymphoma, Follicular
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 2; 1; 1 Participants
Brain and Central Nervous System Tumors · Intraocular Melanoma · Lung Cancer
Primary: Six-month Overall Survival — 67; 11 Participants
Pancreatic Cancer
Primary: Overall Survival（OS） — 10.9; 8.5 months
Calcium Phosphate Kidney Stones
Primary: Urinary Calcium Phosphate Saturation — 2.38; 1.97; 2.19 no units
Postoperative Stage II/III Colon Cancer
Primary: The Cumulative Rates of Participants With NCI-CTCAE Grade 2 or Higher Peripheral Sensory Neuropathy: Up to End of Study Treatment — 11; 11; 18 Participants
T-cell Lymphomas · Relapsed or Refractory
Primary: Maximum Tolerated Dose of Romidepsin — 8; 8 mg/m^2 romidepsin
Hemophilia A
Primary: Change From Baseline in FVIII Activity as Measured by Chromogenic Substrate Assay at Week 52. — 15.13 IU /dL — p=0.0057
Cancer Terminal
Primary: Dignity Impact Scale — 26.3; 26.2; 26.2 score on a scale — p=0.02
Breast Cancer
Primary: Mammogram Recall for Additional Imaging — 11.3; 12.3; 9.8 percentage of women recalled
Food Preferences
Primary: Beverage Calories Purchased, Week 1 — 1.43; 1.40 Logged calories/100mL
Musculoskeletal Pain · Acute Pain
Primary: Effectiveness: Scale — 4.2; 5.1; 4.9; 3.2 score on a scale
Diabetic Neuropathies
Primary: Daily Physical Activity — 8744; 7373 number of steps per week
Respiratory Syncytial Virus Infections
Primary: RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs) — 5876.3; 6935.3 Titers
Persistent Corneal Epithelial Defect
Primary: Percentage of Patients Achieving Corneal Healing (<0.5 mm2 Lesion Size) of the Persistent Corneal Epithelial Defect at 4 Weeks — 5 Participants